Page 9 - 2020 ASCO-GU Canadian Ambassador Program

CONTENT – BLADDER CANCER

TOPIC

Abstract 442: Safety and efficacy of intravesical nadofaragene firadenovec for patients
with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC):

Results from a phase III trial.

Abstract 436: Treatment of high-grade non-muscle invasive bladder carcinoma by

standard number and dose of BCG instillations versus reduced number and standard

dose of BCG instillations: Results of the phase III clinical trial (NIMBUS).

Abstract 437: Randomized phase III trial of dose-dense methotrexate, vinblastine,

doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative
chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results

of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses.